What is the Market Size of Drug-Coated Balloons | Insights, Trends & Growth Analysis 2026

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA10729

Publication Date: Nov 2025

What is the size of Drug-Coated Balloons Market?

According to 6Wresearch internal database and industry insights, the Drug-Coated Balloons Market was valued at USD 0.96 Billion in 2025 and is expected to reach USD 2.31 Billion by 2032, growing at a CAGR of 15% during 2026-2032F.

The main drivers of this growth are the expanding prevalence of coronary and peripheral artery diseases, the increasing adoption of minimally invasive interventional procedures, and the development of advanced balloon delivery systems that enhance patient outcomes and reduce repeat interventions.

Growth Factors for Drug-Coated Balloons Industry

Growing interest in drug-coated balloon therapies as alternatives to stents in complex lesions.
Rising demand for minimally invasive cardiovascular solutions across hospitals and catheterisation labs.
Increasing launch of paclitaxel- and sirolimus-coated balloon products supported by clinical evidence.
Expansion of ambulatory surgical centres offering interventional treatments rather than inpatient hospital procedures.
Development of advanced balloon coatings and device platforms enhancing drug delivery efficacy.

Drug-Coated Balloons Market Trends

The Drug-Coated Balloons Market is witnessing trends such as greater use of sirolimus-coated balloons alongside established paclitaxel devices as clinicians seek improved safety profiles. In addition, use of DCBs in de-novo lesions and small-vessel disease is becoming more common while real-world data and registries are driving adoption. Manufacturers are focusing on digital integration with catheter labs, and reimbursement frameworks are evolving to support DCB adoption.

Emerging Developments in the Drug-Coated Balloons Market

The Drug-Coated Balloons Market is seeing developments like strategic partnerships between device makers and pharmaceutical companies to co-develop next-generation DCBs, the introduction of combination balloons delivering drug plus anti-thrombotic agents, and the expansion of minimally invasive offerings into emerging markets with adoption programs. Further innovation includes biodegradable balloon coatings and robust clinical trial data for broader indications.